Key facts
- It has raised $44.5M; the latest was Later Stage VC in Jul 2025.
- Notable investors include China Capital Management, Infinity Group, ZGC Science City, Yijing Capital, Hankang Capital — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Leto Laboratories
- ·The full record, as it builds
Funding rounds
No funding rounds for Leto Laboratories are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Leto Laboratories
Developer and researcher of advanced directional protein renaturation technology intended to provide effective treatment options for patients worldwide. The company uses advanced technologies such as high-throughput protein re-screening and purification technology platform, fixed point protein coupling design platform, and high-throughput protein drug formulation development platform in their research, enabling clients to develop more effective protein-based drugs.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2014
- Employees
- 48
- Website
- letolab.net/
- Ownership
- Privately Held (backing)
Leto Laboratories doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Leto Laboratories shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Leto Laboratories in its N-PORT filings yet. We sweep new filings monthly.